Celltiter glo luminiscent viability assay

Manufactured by Promega

The CellTiter-Glo Luminescent Viability Assay is a cell-based assay that quantifies the amount of ATP present, which is an indicator of metabolically active cells. It provides a quantitative measure of cell viability and cytotoxicity.

Automatically generated - may contain errors

Lab products found in correlation

Facscanto, by BD (1 mentions) Annexin 5 fitc and 7 aad, by BD (1 mentions) Facsdiva, by BD (1 mentions) Fortessa, by BD (1 mentions)

Spelling variants of this product

CellTiter-Glo (2548 citations) CellTiter-Glo assay (840 citations)

6 protocols using celltiter glo luminiscent viability assay

Cell Viability Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The CellTiter-Glo Luminiscent Viability assay (Promega, Leiden, The Netherlands) was used to measure cell viability according to manufacturer’s instructions. 100,000 cells/ml were treated with the indicated agent and cell viability was measured after 48 h.

Maes A., Maes K., Vlummens P., De Raeve H., Devin J., Szablewski V., De Veirman K., Menu E., Moreaux J., Vanderkerken K, & De Bruyne E. (2019). Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. Blood Cancer Journal, 9(12), 87.

+ Open protocol

+ Expand

Cell viability and apoptosis assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

LP-1(wt) and ANBL-6(wt) cells were treated for 4 hours with 1 or 10μM of AT-406 followed by bortezomib treatment (5 or 10nM). After 24 hours the viability was measured with the CellTiter-Glo Luminiscent Viability assay (Promega, Leiden, The Netherlands) according to manufacturer's instructions. The relative amount of viable cells was expressed as percentage of untreated cells.
Apoptosis was measured with Annexin V-FITC and 7-AAD (BD Biosciences) followed by flow cytometric analysis (FACS Canto and Diva software, BD Biosciences) according to manufacturer's instructions.

Duvefelt C.F., Lub S., Agarwal P., Arngården L., Hammarberg A., Maes K., Van Valckenborgh E., Vanderkerken K, & Wiklund H.J. (2015). Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment. Oncotarget, 6(24), 20621-20635.

+ Open protocol

+ Expand

Cell Viability and qRT-PCR Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell viability was determined by combination of CellTiter Glo Luminiscent viability assay (Promega) and flow cytometric analysis on LSRII or Fortessa (BD Biosciences) and FACSDiva or FlowJo software (BD Biosciences). For viability, we used combination of annexin V/4′,6-diamidino-2-phenylindole stain or the fixable viability Dye eFluro450 (eBioscience).
Quantitative reverse transcription PCR was performed according to standard protocols, and used primer sets are listed in the supplemental Methods.

Goossens S., Peirs S., Van Loocke W., Wang J., Takawy M., Matthijssens F., Sonderegger S.E., Haigh K., Nguyen T., Vandamme N., Costa M., Carmichael C., Van Nieuwerburgh F., Deforce D., Kleifeld O., Curtis D.J., Berx G., Van Vlierberghe P, & Haigh J.J. (2017). Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia. Blood, 129(8), 981-990.

+ Open protocol

+ Expand

Cell Viability Assay in 96-well Plate

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells (1 × 10⁴) were seeded into 96 well plates. Treatment as described in the figure legends was initiated the following day. Cell viability was determined 18 hours after treatment using CellTiter-Glo Luminiscent Viability Assay (Promega, Madison, WI). Data were recorded with a SpectraMax Gemini microplate spectrofluorometer, Molecular Devices (Silicon Valley, CA).

Garg G., Vangveravong S., Zeng C., Collins L., Hornick M., Hashim Y., Piwnica-Worms D., Powell M.A., Mutch D.G., Mach R.H., Hawkins W.G, & Spitzer D. (2014). Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. Molecular Cancer, 13, 50.

+ Open protocol

+ Expand

Assessing Cell Viability via Luminescence

Check if the same lab product or an alternative is used in the 5 most similar protocols

The viability was measured with the CellTiter-Glo Luminiscent Viability assay (Promega, Leiden, The Netherlands) according to manufacturer's instructions. The relative amount of viable cells was expressed as percentage of untreated cells.

Lub S., Maes A., Maes K., De Veirman K., De Bruyne E., Menu E., Fostier K., Kassambara A., Moreaux J., Hose D., Leleu X., King R.W., Vanderkerken K, & Van Valckenborgh E. (2015). Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget, 7(4), 4062-4076.

+ Open protocol

+ Expand

Cell Viability Assay for Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

OVCAR3, HeLa, and Jurkat cells were seeded in 96 well plates. Unless otherwise stated, the cells were treated the following day and assayed 18 hours later using CellTiter-Glo Luminiscent Viability Assay (Promega, Madison, WI). Data were recorded with a SpectraMax Gemini microplate spectrofluorometer, Molecular Devices (Silicon Valley, CA).

Garg G., Gibbs J., Belt B., Powell M.A., Mutch D.G., Goedegebuure P., Collins L., Piwnica-Worms D., Hawkins W.G, & Spitzer D. (2014). Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC Cancer, 14, 35.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!